Abstract Number: 1269 • ACR Convergence 2021
The Burden of Systemic Lupus Erythematosus Patients in the United States – Evidence from the Medical Expenditure Panel Survey (2016-2018)
Background/Purpose: Due to the heterogeneity of systemic lupus erythematosus (SLE), clinical characteristics, quality of life (QOL), social determinant of health (SDOH), health care utilization (HRU),…Abstract Number: 0135 • ACR Convergence 2021
Comparing Rheumatoid Arthritis (RA), Psoriatic Arthritis (PA) and Systemic Lupus Erythematosus (SLE) Total Cost of Care (TCC) in Those with Optimally Managed Depression to Those with Sub-optimally Managed Depression
Background/Purpose: Rheumatic diseases (RD) are characterized by systemic signs and symptoms, including articular and extra-articular manifestations. Three common forms of RDs are RA, PsA and…Abstract Number: 0143 • ACR Convergence 2021
Economic and Healthcare Resource Use Burden of Systemic Sclerosis
Background/Purpose: The clinical burden of systemic sclerosis (SSc) is substantial and typically characterized by progressive skin, gastrointestinal, pulmonary, and cardiovascular complications and premature death. The…Abstract Number: 0228 • ACR Convergence 2021
Optimizing Social Media as a Recruitment Tool for Hard-to-Reach Populations in Rheumatology Clinical Research
Background/Purpose: Standard methods of recruitment for clinical research, such as traditional media advertisements, can be inefficient and expensive, especially for underserved communities and asymptomatic individuals.…Abstract Number: 0465 • ACR Convergence 2021
Cost-effectiveness of Treatment Strategies Involving Arthroscopic Partial Meniscectomy and Physical Therapy for Degenerative Meniscal Tear
Background/Purpose: Knee osteoarthritis (KOA) and meniscal tear (MT) are highly prevalent and often concomitant. Treatments for MT in the presence of KOA include physical therapy…Abstract Number: 0576 • ACR Convergence 2020
Medical Savings of Timely Rheumatoid Arthritis Diagnoses
Background/Purpose: Previous studies suggest that early rheumatoid arthritis (RA) recognition and treatment provides greater clinical benefits than treatment started later in the disease course. However,…Abstract Number: 0579 • ACR Convergence 2020
Risk Factors of Nonadherence in New Rheumatoid Arthritis Patients
Background/Purpose: Biologic disease-modifying antirheumatic drug (bDMARD) therapies are commonly prescribed for rheumatoid arthritis (RA) treatment. However, their high out-of-pocket (OOP) cost may limit patient access…Abstract Number: 0582 • ACR Convergence 2020
Mortality and Cost of Hospitalization: Do Hospitals Caring for More SLE Patients Perform Better?
Background/Purpose: Individuals with systemic lupus erythematosus (SLE) have an increased risk of hospitalization throughout their lifetime, potentially leading to higher patient mortality and healthcare costs.…Abstract Number: 0583 • ACR Convergence 2020
Cost of Illness in Patients with Psoriasis and Psoriatic Arthritis
Background/Purpose: Psoriasis (Ps) and psoriatic arthritis (PsA) have a major impact on patients’ health-related quality of life. Cost of illness of patients with Ps, PsA and…Abstract Number: 0584 • ACR Convergence 2020
Total Cost of Care for Patients with Rheumatoid Arthritis
Background/Purpose: The range of medical costs associated with rheumatoid arthritis (RA) is, in part, related to the various treatment options. Treatment for RA focuses on…Abstract Number: 0585 • ACR Convergence 2020
Cost-effectiveness of Motivational Counselling and SMS-reminders on Daily Sitting Time in Patients with Rheumatoid Arthritis
Background/Purpose: The “Joint Resources – Sedentary Behaviour” randomised controlled trial (RCT) (1,2,3) aimed to reduce sedentary behaviour in patients with rheumatoid arthritis (RA) by means…Abstract Number: 0588 • ACR Convergence 2020
Feast or Famine? An Institutional Assessment of Hydroxychloroquine Screening Practices
Background/Purpose: Hydroxychloroquine (HCQ) is a generally safe and widely used rheumatologic drug. Maculopathy is an adverse effect in < 1% in the first 5 years…Abstract Number: 0609 • ACR Convergence 2020
Impact of Depressive Symptoms, Anti-depression Treatment on Direct Medical Costs Among Medicare Beneficiaries with Knee Osteoarthritis (KOA)
Background/Purpose: Depressive symptoms are prevalent among knee OA (KOA) patients and likely lead to additional medical costs. We sought to quantify the prevalence of depressive…Abstract Number: 1265 • ACR Convergence 2020
2019 Lupus Classification Criteria Score Predicting Cost of Future Hospitalizations
Background/Purpose: The latest 2019 Lupus Classification criteria score (CCS) is based on weighted criteria and has been shown to predict 10-year mortality1. Our previous study…Abstract Number: 1618 • ACR Convergence 2020
Frequency and Cost of Repeat HLA-B27 Testing Within the National Capital Consortium over a Calendar Year
Background/Purpose: Human leukocyte antigens (HLAs) are proteins encoded for by the major histocompatibility complex located on the short arm of chromosome six. One such allele,…